Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function and Reduces Exacerbation Rate and Risk in Phase 3 Enhance-2 Trial

被引：0
|
作者：
Anzueto, A. [1 ]
Barjaktarevic, I. [2 ]
Rheault, T. [3 ]
Bengtsson, T. [4 ]
Rickard, K. [3 ]
机构：
[1] Univ Texas Hlth Med San Antonio, Med Pulm Crit Care, San Antonio, TX USA
[2] UCLA, Pulm & Crit Care, Los Angeles, CA USA
[3] Verona Pharma, Raleigh, NC USA
[4] StatMind AB, Lund, Sweden
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4494
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Ensifentrine, A Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Provides Effective Bronchodilation in COPD When Administered Twice Daily Over 7 Days Via a Dry Powder Inhaler
    Rheault, T.
    Rickard, K.
    Boscia, J. A.
    Bengtsson, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [22] A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy
    Ferguson, Gary T.
    Kerwin, Edward M.
    Rheault, Tara
    Bengtsson, Thomas
    Rickard, Kathleen
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2021, 16 : 1137 - 1148
  • [23] Safety of Ensifentrine, a Dual PDE3/4 Inhibitor: Results of Reported GI and CV Events from a Four Week Randomized, Controlled Trial
    Rickard, K.
    Rheault, T.
    Bengtsson, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [24] Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)
    Anzueto, Antonio
    Barjaktarevic, Igor Z.
    Siler, Thomas M.
    Rheault, Tara
    Bengtsson, Thomas
    Rickard, Kathleen
    Sciurba, Frank
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 208 (04) : 406 - 416
  • [25] Bronchodilation and Symptom Improvement with Ensifentrine, A Dual PDE3/4 Inhibitor: Sub-Group Analyses of a Four Week Randomized, Controlled Trial in Patients with COPD
    Rheault, T.
    Rickard, K.
    Bengtsson, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [26] Safety of Dual PDE3/4 Inhibitor Ensifentrine Added to Tiotropium: Gastrointestinal and Cardiovascular Adverse Events from a Four-Week Randomized, Controlled Trial
    Rickard, K.
    Bengtsson, T.
    Rheault, T.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [27] Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)
    Bhatt, Surya P.
    Rabe, Klaus F.
    Hanania, Nicola A.
    Vogelmeier, Claus F.
    Bafadhel, Mona
    Christenson, Stephanie A.
    Papi, Alberto
    Singh, Dave
    Laws, Elizabeth
    Dakin, Paula
    Maloney, Jennifer
    Lu, Xin
    Bauer, Deborah
    Bansal, Ashish
    Robinson, Lacey B.
    Abdulai, Raolat M.
    RESPIRATORY MEDICINE, 2025, 236
  • [28] Dupilumab Improves Lung Function and Reduces Severe Exacerbation Rate in Patients With Uncontrolled, Moderate-to-Severe Asthma With or Without Comorbid Allergic Rhinitis: Results From the Phase 3 LIBERTY ASTHMA QUEST Study
    Busse, William W.
    Maspero, Jorge F.
    Hanania, Nicola A.
    Fitz-Gerald, J. Mark
    Ford, Linda B.
    Rice, Megan
    Lu, Yufang
    Rowe, Paul
    Staudinger, Heribert
    Amin, Nikhil
    Ruddy, Marcella
    Graham, Neil M. H.
    Teper, Ariel
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB97 - AB97
  • [29] DUPILUMAB REDUCES EXACERBATIONS AND IMPROVES LUNG FUNCTION IN UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA PATIENTS REGARDLESS OF PRIOR EXACERBATION HISTORY IN THE PHASE 3 LIBERTY ASTHMA QUEST STUDY
    Pavord, I.
    Ford, L. B.
    Corren, J.
    Kuna, P.
    Dong, Q.
    Staudinger, H.
    Maroni, J.
    Rowe, P.
    Rout, R.
    Amin, N.
    Akinlade, B.
    Graham, N. M. H.
    Teper, A.
    THORAX, 2018, 73 : A121 - A122
  • [30] EFFICACY OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, ON PHYSICAL FUNCTION AND PAIN IN PATIENTS WITH PSORIATIC ARTHRITIS AND CURRENT SKIN INVOLVEMENT: RESULTS OF PALACE 3, A PHASE 3, RANDOMIZED, CONTROLLED TRIAL
    Edwards, Christopher J.
    Blanco, Francisco J.
    Crowley, Jeffrey
    Hu, ChiaChi
    Stevens, Randall M.
    Birbara, Charles A.
    RHEUMATOLOGY, 2014, 53 : 139 - 140
12345